BLISSGVS

Bliss GVS Pharma Limited

Formulations and APIs for women's health and other segments

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

blissgvs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹652.00
Market cap
6,906 Cr
Stock P/E
50.7
P/B
5.77
Dividend yield
0.2%
ROE (FY26)
10.5%
ROCE (FY26)
16.3%
Operating margin (FY26)
14.1%
Debt / equity (FY26)
0.0025
OCF / EBITDA (FY26)
84.6%
OCF / EBITDA (3Y)
90.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Bliss GVS Pharma makes pharmaceutical formulations, including suppositories and pessaries, and sells mainly into Sub-Saharan Africa.

Company snapshot

51stBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓90% of operating profit came in as cash over the last three years — profits are backed by real cash.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales212 Cr201 Cr198 Cr184 Cr218 Cr210 Cr198 Cr207 Cr244 Cr218 Cr257 Cr286 Cr
Operating expenses (approx.)158 Cr157 Cr170 Cr149 Cr176 Cr181 Cr177 Cr166 Cr213 Cr183 Cr213 Cr209 Cr
EBITDA54 Cr44 Cr28 Cr34 Cr41 Cr30 Cr21 Cr41 Cr32 Cr35 Cr44 Cr76 Cr
OPM %25.7%21.8%14.3%18.7%19.1%14.2%10.7%19.9%13.0%15.9%17.3%26.8%
Other income13 Cr5 Cr6 Cr4 Cr5 Cr15 Cr12 Cr35 Cr20 Cr18 Cr11 Cr10 Cr
Interest1 Cr2 Cr2 Cr2 Cr4 Cr1 Cr2 Cr5 Cr3 Cr1 Cr2 Cr0.58 Cr
Depreciation6 Cr7 Cr7 Cr7 Cr7 Cr8 Cr8 Cr8 Cr8 Cr8 Cr9 Cr10 Cr
Profit before tax59 Cr40 Cr-4 Cr30 Cr36 Cr36 Cr23 Cr63 Cr41 Cr41 Cr45 Cr75 Cr
Tax %27.2%27.4%-24.4%26.5%28.0%29.1%29.0%29.7%29.6%39.4%17.7%31.9%
Net profit43 Cr29 Cr-5 Cr22 Cr26 Cr26 Cr17 Cr44 Cr29 Cr25 Cr37 Cr51 Cr
EPS (₹)₹4.06₹2.64₹-0.88₹1.97₹2.31₹2.27₹1.47₹4.08₹2.58₹2.20₹3.37₹4.73

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales407 Cr373 Cr898 Cr689 Cr577 Cr747 Cr752 Cr770 Cr810 Cr927 CrSign in free for the trailing twelve months
Operating expenses (approx.)304 Cr276 Cr741 Cr566 Cr471 Cr629 Cr634 Cr620 Cr683 Cr763 CrSign in free for the trailing twelve months
EBITDA103 Cr96 Cr158 Cr123 Cr107 Cr118 Cr117 Cr151 Cr127 Cr164 CrSign in free for the trailing twelve months
OPM %25.3%25.8%17.5%17.9%18.5%15.8%15.6%19.6%15.6%17.7%Sign in free for the trailing twelve months
Other income9 Cr20 Cr38 Cr37 Cr20 Cr31 Cr18 Cr29 Cr36 Cr74 CrSign in free for the trailing twelve months
Interest13 Cr9 Cr4 Cr5 Cr6 Cr5 Cr10 Cr7 Cr8 Cr12 CrSign in free for the trailing twelve months
Depreciation11 Cr9 Cr9 Cr13 Cr17 Cr17 Cr19 Cr26 Cr29 Cr33 CrSign in free for the trailing twelve months
Profit before tax88 Cr64 Cr182 Cr129 Cr104 Cr54 Cr106 Cr117 Cr126 Cr190 CrSign in free for the trailing twelve months
Tax %41.4%50.4%30.4%26.1%29.0%57.3%27.7%30.2%28.2%28.9%Sign in free for the trailing twelve months
Net profit113 Cr89 Cr127 Cr95 Cr74 Cr23 Cr77 Cr82 Cr90 Cr135 CrSign in free for the trailing twelve months
EPS (₹)₹7.95₹5.70₹11.99₹9.43₹6.64₹1.46₹6.83₹7.23₹8.02₹12.23Sign in free for the trailing twelve months
Dividend payout %————7.5%23.0%7.1%6.6%6.0%8.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital10 Cr10 Cr10 Cr10 Cr10 Cr10 Cr10 Cr10 Cr11 Cr11 Cr
Reserves476 Cr526 Cr636 Cr725 Cr798 Cr808 Cr873 Cr957 Cr1,040 Cr1,182 Cr
Borrowings213 Cr112 Cr97 Cr104 Cr98 Cr105 Cr98 Cr88 Cr71 Cr3 Cr
Other liabilities257 Cr201 Cr148 Cr175 Cr151 Cr157 Cr141 Cr123 Cr138 Cr258 Cr
Total liabilities1,023 Cr860 Cr905 Cr1,029 Cr1,077 Cr1,109 Cr1,157 Cr1,214 Cr1,301 Cr1,492 Cr
Fixed assets (net)255 Cr126 Cr135 Cr233 Cr225 Cr273 Cr370 Cr362 Cr397 Cr451 Cr
CWIP4 Cr0.47 Cr47 Cr0 Cr2 Cr22 Cr3 Cr8 Cr21 Cr6 Cr
Investments0.19 Cr0.02 Cr0.72 Cr0.72 Cr0.70 Cr3 Cr8 Cr5 Cr5 Cr6 Cr
Loans & advances——0.32 Cr0.17 Cr0.16 Cr0.13 Cr0.10 Cr0.07 Cr0.04 Cr0.04 Cr
Inventories49 Cr59 Cr77 Cr74 Cr99 Cr124 Cr103 Cr118 Cr126 Cr151 Cr
Trade receivables254 Cr298 Cr461 Cr548 Cr464 Cr393 Cr385 Cr404 Cr438 Cr517 Cr
Cash & bank47 Cr43 Cr15 Cr15 Cr13 Cr22 Cr25 Cr23 Cr24 Cr35 Cr
Other assets413 Cr333 Cr169 Cr158 Cr273 Cr272 Cr262 Cr294 Cr290 Cr327 Cr
Total assets1,023 Cr860 Cr905 Cr1,029 Cr1,077 Cr1,109 Cr1,157 Cr1,214 Cr1,301 Cr1,492 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity289 Cr18 Cr40 Cr45 Cr64 Cr135 Cr34 Cr152 Cr106 Cr139 Cr
Cash from investing-231 Cr56 Cr-74 Cr-49 Cr-47 Cr-93 Cr-8 Cr-133 Cr-75 Cr-38 Cr
Cash from financing-10 Cr-76 Cr17 Cr-4 Cr-21 Cr-24 Cr-25 Cr-21 Cr-30 Cr-89 Cr
Net cash flow48 Cr-2 Cr-17 Cr-7 Cr-2 Cr19 Cr3 Cr-1 Cr0.23 Cr11 Cr
Free cash flow (OCF − Capex)186 Cr-11 Cr-4 Cr-15 Cr55 Cr135 Cr-59 Cr124 Cr30 Cr82 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %13.2%11.0%24.6%15.7%11.8%6.2%11.5%11.3%11.5%16.3%
ROE %14.8%10.7%18.7%13.0%8.3%1.8%7.7%7.5%7.7%10.5%
Debtor days227292187290292191187192197203
Inventory days106112130105139117114127123142
Days payable2101111321341048795667098
Cash conversion cycle123293184262327221205253250247
OCF / EBITDA %281.2%18.3%25.3%36.7%60.0%114.5%29.2%101.2%83.6%84.6%
OCF / EBITDA % (3 years)——97.3%27.3%38.5%70.3%68.3%83.4%74.2%90.0%
Debt / equity0.440.210.150.140.120.130.110.090.070.0025
Current ratio1.292.303.353.333.763.333.615.084.774.02
Net debt / EBITDA1.610.710.520.720.800.700.620.430.37-0.20